An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin.
It is now well established that liposomes with surface associated proteins are immunogenic. Repeated administration of protein coated liposomes elicits the generation of antibodies and the elimination of proteoliposome increases markedly in animals 'immunized' with such liposomes. This immune response compromises the therapeutic potential of liposomal formulations that rely on the use of protein- or peptide-based targeting ligands to enhance cell specificity. Strategies to suppress or inhibit such immune responses must be developed if this technology is going to prove therapeutically viable. This study evaluates whether an immune response to a protein, covalently attached to liposomes by a thioether bond between N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP)-modified-protein and N-(4-(P-maleimidophenyl)butyryl) (MPB)-activated lipids, can be suppressed when the liposomes used contain the anti-cancer drug doxorubicin. To assess this, the highly immunogenic protein ovalbumin was conjugated onto liposomes composed of distearoylphosphatidylcholine/cholesterol (DSPC/Chol) with sufficient poly(ethylene glycol)-modified distearoyl phosphatidylethanolamine (PEG-DSPE) (2 mol%) to prevent liposome aggregation during protein coupling and to engender increased circulation lifetimes. The immune response to these liposomes with and without encapsulated doxorubicin was measured by: (1) monitoring liposome elimination after 3 weekly i.v. injections in C3H/HeJ mice and (2) measuring the anti-ovalbumin antibody levels by an ELISA assay. One week after a single dose of ovalbumin-coated PEG liposomes (50 microg protein/mouse) the immune response resulted in rapid elimination of a second dose of ovalbumin-coated PEG liposomes. Rapid liposome elimination was correlated to generation of high levels (> 9 microg/ml plasma) of circulating anti-ovalbumin IgG. In contrast, anti-ovalbumin antibodies were not detected when the liposomes used contained doxorubicin. Plasma elimination of these drug loaded protein coated liposomes decreased following repeated weekly i.v. doses, an effect that is consistent with liposomal doxorubicin mediated suppression of phagocytic cells in the liver.
Tardi
P G
PG
Inex Pharmaceutical Corp., Burnaby, British Columbia, Canada.
Swartz
E N
EN
Harasym
T O
TO
Cullis
P R
PR
Bally
M B
MB
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000917:Antibody Formation; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D000922:Immunotoxins / Q000276:immunology; D008081:Liposomes / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology*
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D000922:Immunotoxins; D008081:Liposomes; D004317:Doxorubicin; D010047:Ovalbumin